Urolithin A, a novel natural compound to target PI3K/AKT/mTOR pathway in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy and is highly resistant to standard treatment regimens. Targeted therapies against KRAS, a mutation present in an overwhelming majority of PDAC cases, have been largely ineffective. However, inhibition of downstream components in th...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Mol Cancer Ther
Autores principales: Totiger, Tulasigeri M., Srinivasan, Supriya, Jala, Venkatakrishna R., Lamichhane, Purushottam, Dosch, Austin R., Gaidarski, Alexander A., Joshi, Chandrashekhar, Rangappa, Shobith, Castellanos, Jason, Vemula, Praveen Kumar, Chen, Xi, Kwon, Deukwoo, Kashikar, Nilesh, VanSaun, Michael, Merchant, Nipun B., Nagathihalli, Nagaraj S.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2018
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6363854/
https://ncbi.nlm.nih.gov/pubmed/30404927
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-18-0464
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares